Posters

Visual acuity improvement in AMD patients implanted with the iolAMD Eyemax IOL

Poster Details

First Author: E.Villegas SPAIN

Co Author(s):    A. Pio   L. Hervella   J. Marin   M. Qureshi   P. Artal        

Abstract Details

Purpose:

To assess visual acuity changes in patients diagnosed with both incipient cataracts and dry/atrophic age-related macular degeneration (AMD) after cataract surgery with bilateral implantation of the IOLAMD Eyemax IOL.

Setting:

University Hospital Virgen de la Arrixaca, Murcia, Spain

Methods:

Ten patients were diagnosed with dry/atrophic AMD and were graded as level 1-2 of nuclear cataract according to the LOCS III scale. They were implanted bilaterally with IOLAMD Eyemax IOLs (London Eye Hospital Pharma, UK). This is a pseudophakic single lens with optimized optical design for retinal eccentricities up to 10 degrees. The IOL�â�€�™s power was selected to render each eye sub-corrected (hyperopic �.00 D), to assure a retinal magnification with external spectacles. Pre and post-surgery best corrected visual acuity (VA) were measured at far (4 m) and near (33 cm) distances using a VA test with 0.1-LogMAR steps.

Results:

After surgery, the mean spherical equivalent refractive error was �.00�Â�±0.60 D with astigmatism values bellow 2.00 D. At both viewing distances, the inter-subject mean values of pre-op LogMAR VA were 0.90 and 0.75 for monocular and binocular measurements respectively. These values improved between 0.21 and 0.24 LogMAR after surgery. There was variability in the VA improvements between eyes ranging from 0 to 0.65 in LogMAR and from 0 to 33 letters read.

Conclusions:

In AMD patients with incipient cataract, we found a significant improvement in visual acuity after IOLAMD Eyemax IOL implantation. Binocular improvement occurs in 9 of the 10 tested eyes. AMD patients with cataracts implanted with bilaterally could improve their visual acuity exceeding the physiological values corresponding to their retinal fixation area.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented